Proteintech and HebeCell announce
their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor (nCAR)
technology for the development and commercialization of iPSC-derived natural killer (iPSC-nCAR-NK)
cells, a promising cellular immunotherapy treatment for cancer and other diseases.
their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor (nCAR)
technology for the development and commercialization of iPSC-derived natural killer (iPSC-nCAR-NK)
cells, a promising cellular immunotherapy treatment for cancer and other diseases.
Ankarys Therapeutics Inc. (Ankarys), Applied StemCell, Inc. (ASC), and HebeCell Corp. (HebeCell) announced that they have entered into a strategic collaboration to co-develop allogeneic induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR) NK cell therapeutics targeting hematological malignancies.